You might also like
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates for oncology. The company is dedicated to addressing significant unmet needs in cancer treatment by creating novel small molecules that enhance the efficacy of existing drugs. Nuvation Bio does not currently sell products but is engaged in research and development activities, with a focus on advancing its clinical-stage product candidates.
- NUV-868 - A BD2-selective oral small molecule BET inhibitor, evaluated in combination with other drugs for treating various cancers, including ovarian, pancreatic, and prostate cancers, as well as triple-negative breast cancer and other solid tumors.
- NUV-1511 - The first clinical candidate from the Drug-Drug Conjugate platform, undergoing evaluation in a Phase 1/2 study for advanced solid tumors.
- Taletrectinib - An oral, potent, CNS-active, selective, next-generation ROS1 inhibitor for advanced ROS1-positive non-small cell lung cancer, acquired through the acquisition of AnHeart Therapeutics Ltd. and evaluated in Phase 2 studies.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
David Hung, M.D. ExecutiveBoard | President, CEO, and Board Member | None | Founder of NUVB in April 2018; previously founded Medivation, Inc., leading development of Xtandi\u00ae and Talzenna\u00ae; Medivation was acquired by Pfizer for $14.3 billion. | |
Junyuan (Jerry) Wang, Ph.D. ExecutiveBoard | CEO of AnHeart Therapeutics and Director | None | Co-founder of AnHeart Therapeutics; led development of taletrectinib and safusidenib; extensive global regulatory experience; contributed to NDAs for Bosulif and Eliquis. | |
Colleen Sjogren Executive | Chief Commercial Officer | None | Joined NUVB in April 2024; previously held senior sales roles at Madrigal Pharmaceuticals, Mirati Therapeutics, and Kite Pharma. | |
Kerry Wentworth Executive | Chief Regulatory Officer | None | Joined NUVB in May 2022; previously Chief Regulatory Officer at Flexion Therapeutics; extensive regulatory leadership experience at Agenus and Genzyme. | |
Moses Makunje, CPA Executive | VP, Finance, Principal Financial and Accounting Officer | None | Joined NUVB in July 2020; promoted to VP, Finance in January 2022; appointed Principal Financial and Accounting Officer in November 2023; 16+ years of finance experience. | |
Philippe Sauvage Executive | Chief Financial Officer | None | Appointed CFO in October 2024; previously held senior finance roles at Sanofi, including CFO for Sanofi North America and Sanofi-Genzyme. | |
Stacy Markel Executive | Chief People Officer | None | Joined NUVB in October 2019 as SVP, Human Resources; promoted to Chief People Officer in January 2022; extensive HR leadership experience at Rigel Pharmaceuticals and Portola Pharmaceuticals. | |
Kathryn E. Falberg Board | Board Member, Chair of Audit Committee | Arcus Biosciences, The Trade Desk, Inc. | Former CFO of Jazz Pharmaceuticals and Amgen; extensive finance and strategy experience; serves on boards of Arcus Biosciences and The Trade Desk. | |
Kim Blickenstaff Board | Board Member | Executive Chairman and Chairman of Tandem Diabetes Care, Inc. | Extensive leadership experience in healthcare and medical devices; previously CEO of Biosite Incorporated; serves as Executive Chairman and Chairman of Tandem Diabetes Care. | |
W. Anthony Vernon Board | Board Member, Chair of Compensation Committee | NovoCure Ltd., Intersect ENT, Inc., McCormick & Co. | Former CEO of Kraft Foods Group; held senior roles at Johnson & Johnson; serves on boards of NovoCure, Intersect ENT, and McCormick & Co.. | |
Xiangmin (Min) Cui, Ph.D. Board | Board Member | Managing Director at Decheng Capital LLC; Board Member at Alpine Immune Sciences and multiple private companies | Founder of Decheng Capital; extensive leadership in biotech and pharma; serves on boards of Alpine Immune Sciences and several private companies. |
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
A large pharmaceutical company that has commercialized and/or is developing treatments for cancer, including therapies targeting hormone receptor pathways in cancer cells. These therapies are used for tumors such as ER+ mBC, prostate cancer, and ovarian cancer. | |
A large pharmaceutical company involved in the development of cancer therapies, including BET inhibitors for hematological malignancies and solid tumors. | |
A large pharmaceutical company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells. | |
A large pharmaceutical company that has commercialized and/or is developing treatments for cancer. | |
A large pharmaceutical company involved in the development of cancer therapies, including hormone receptor-targeting treatments. | |
A large pharmaceutical company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells. | |
A partnership involved in the development of cancer therapies. | |
Roche | A large pharmaceutical company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells. |
Constellation Pharma/MorphoSys Company | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
Opna Bio | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
Plexxikon | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
Zenith Epigenetics | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. | |
Boehringer Ingelheim | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. | |
Jacobio | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. | |
A large pharmaceutical company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells and clinical-stage BET inhibitors. | |
Betta Pharmaceuticals | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
Ranok Therapeutics | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
Epigenetix | A company developing clinical-stage BET inhibitors for hematological malignancies and solid tumors. |
Bayer | A large pharmaceutical company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells. |
Clovis Oncology | A company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells. |
Dendreon | A company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells. |
Janssen Pharmaceutical Companies | A company developing cancer treatments, including therapies targeting hormone receptor pathways in cancer cells. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
AnHeart Therapeutics, Ltd. | 2025 | No specific deal value or structure details were provided; the integration into Nuvation Bio Inc. was completed via a merger which led to the departure of CEO Dr. Jerry Wang and was aimed at achieving regulatory approvals for taletrectinib. |
No recent press releases or 8-K filings found for NUVB.